The Lipid Testing segmentation by application distinguishes four principal demand drivers. Clinical diagnostics dominates the market, accounting for roughly 55% of total revenue, as hospitals and reference labs require high‑throughput, validated assays for cholesterol, triglycerides, and lipoprotein fractions to guide therapeutic decisions. Preventive health screening contributes about 25%; this segment includes wellness programs, employer‑sponsored health checks, and direct‑to‑consumer testing, where cost‑effective, automated platforms drive volume growth. Pharmaceutical research represents 15% of the market, encompassing drug development studies that rely on precise lipid profiling to assess metabolic effects and safety endpoints, thereby prompting adoption of specialized, high‑sensitivity methods. Finally, academic research occupies the remaining 5%, supporting exploratory studies and method development in university labs. Collectively, these applications shape the overall Lipid Testing market size by dictating investment in instrumentation, reagent consumption, and service contracts, with each segment’s proportional share reflected in the accompanying pie‑chart.